Recombinant adeno-associated virus
(AAV) vectors have emerged as a new vector for gene therapy, and they have been widely used in clinical trials to treat a variety of diseases.
Samulski, "Adeno-associated virus
terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo," Gene Therapy, vol.
Investigators are testing a variety of ways to deliver potentially therapeutic genes through direct injection of vascular endothelial growth factor (VEGF) DNA into muscles or via vectors created from adeno-associated virus
or herpes simplex virus (HSV).
announced today that Pfizer (NYSE:PFE) has exercised the option, granted in a collaboration and license agreement previously announced in January 2008, to further develop and commercialise Tacere's Hepatitis C Virus (HCV) compounds.The lead clinical candidate is a new class of agent containing three separate RNAi elements, simultaneously targeting three different sites of the Hepatitis C virus, and encapsidated in an adeno-associated virus
(AAV) protein coat.
MATERIALS AND METHODS: Recombinant adeno-associated virus
encoding rat leptin cDNA (rAAV-leptin) or control vector were administered by intracerebroventricular injection to lean F344 x BN rats for up to 150 days, and food consumption, body weight, serum leptin and glucose tolerance were measured.
Articles have recently appeared in the literature reporting the use of adeno-associated virus
vectors (AAV) expressing phenylalanine hydroxylase (PAH) in animal trials and suggesting its use in treatment of phenylketonuria (PKU) as a form of gene therapy (1-3).
Their topics include possible retrovirus vectors, adeno and adeno-associated virus
vectors, gene therapy for acute renal failure due to ischemia-reperfusion issues and acute injuries, and treatment for chronically deteriorating renal function and renal fibrosis, and treatment for acute and chronic allograft rejection.
Ertl of the Wistar Institute in Philadelphia to call for a pause in human tests of the vaccine that delivers snippets of HIV to people via a genetically altered adeno-associated virus
A RECOMBINANT AVIAN ADENO-ASSOCIATED VIRUS
AS A VECTOR FOR INFECTIOUS BURSAL DISEASE VACCINATION.
Genzyme Corp., Cambridge, MA, announced it has acquired extensive gene therapy assets from Avigen, Inc., Alameda, CA, including rights to a broad patent estate focused on adeno-associated virus
technology, a Phase 1/2 clinical development program in Parkinson's disease, and a clinical collaboration in hemophilia.
Targeted Genetics Corporation (Seattle, WA) announced the issuance of a patent covering additional approaches to manufacturing AAV (adeno-associated virus
Phase I trial results using an adeno-associated virus
injected into muscle to provide factor IX provide hope for patients with this disease.